What is it?
A concentrated choline donor
1Alpha-GPC, also called choline alfoscerate, is a choline-containing glycerophospholipid. The shorter name is common on consumer labels, while clinical papers often use choline alfoscerate.
Names, aliases and forms
Mechanisms of action
A choline source, not a guaranteed cognition result
2Alpha-GPC is a choline source, and choline is involved in acetylcholine synthesis and cell-membrane components. This biochemical role does not by itself establish a cognitive outcome.
Potential effects and evidence map
Pooled trials in adult-onset cognitive dysfunction report cognitive outcomes, but their populations and frequent add-on designs do not establish broad healthy-user benefits. A small acute trial in 20 resistance-trained men reported some Stroop findings but no N-Back or Flanker advantage. The long-term stroke association is observational rather than causal evidence.
In adult-onset cognitive dysfunction, pooled trials report cognitive outcomes. Those clinical populations and frequent add-on designs do not establish a broad memory benefit for healthy adults.
In a 20-person crossover study of resistance-trained men, 315 and 630 mg had some Stroop findings at the 60-minute assessment, while N-Back and Flanker results did not differ. This is narrow evidence, not a general focus claim.
Typical dosages and timing
A 20-person crossover study in resistance-trained men gave either 315 or 630 mg once, with cognitive testing 60 minutes later. That design does not set a general use plan.
Timing & effect horizon
Safety, side effects and risk profile
A South Korean prescription cohort found an association between Alpha-GPC exposure and later stroke. The design cannot determine whether Alpha-GPC caused the outcome or whether results transfer to every user.
NIH lists fishy body odor, vomiting, sweating, low blood pressure, and liver toxicity with high total choline intake; this guidance is not Alpha-GPC-specific.
Clinical evidence in adult-onset cognitive dysfunction does not establish a broad benefit for healthy nootropic use.
The current EU safety opinion covers a defined soy-lecithin-derived ingredient under proposed conditions of use, not every Alpha-GPC product or dose.
NIH describes fishy body odor, vomiting, excessive sweating or salivation, low blood pressure, and liver toxicity with high total choline intake. It is general choline guidance rather than an Alpha-GPC-specific adverse-event rate.
Interactions and cautions
Diet, fortified foods, and supplements can all contribute to total choline intake. NIH reports no known clinically relevant medication interactions for choline; that statement is not Alpha-GPC-specific interaction testing.
Legal and regulatory status
When an Alpha-GPC product is marketed as a U.S. dietary supplement, FDA's dietary-supplement framework applies to its labeling. This page is ingredient research and comparison content; it does not make disease claims.
EFSA assessed a specific L-alpha-GPC ingredient derived from soya lecithin at proposed supplement use up to 203.7 mg/day and found no safety concern under those proposed conditions. Its consideration of pregnancy and lactation is limited to that same ingredient and use context. This is not a general EU status statement for every Alpha-GPC product, form, or dose, including higher study doses.
How it compares
A 2023 review pooled clinical studies in adult-onset cognitive dysfunction. Those results are useful context, but they do not provide a universal focus or memory conclusion for healthy adults.
Practical buying and quality notes
- Compare Alpha-GPC products like for like: labelled amount, powder versus capsule form, serving count, and any test or certificate-of-analysis claim. Compare powder per gram with capsules per capsule or serving; a lower price in a different amount or form is not automatically directly comparable.1
FAQ
Does Alpha-GPC help healthy adults focus?
9One small 2024 crossover study in 20 resistance-trained men reported some Stroop results after 315 or 630 mg, while N-Back and Flanker did not differ. Larger, more diverse and prospectively registered studies are still needed.
What daily amount has been studied?
6In a 12-week MCI trial, the study group received a 600 mg Alpha-GPC soft capsule daily. The population was not a general healthy-user sample.
How long has Alpha-GPC been studied?
6The recent MCI trial ran 12 weeks. That research window describes a study duration; it does not set a cycle length for buyers.
What is the cardiovascular safety signal?
7A South Korean observational cohort linked Alpha-GPC exposure with higher later stroke incidence. The study cannot prove that Alpha-GPC caused the association.
References
- PubChem Compound Summary for Choline Alfoscerate. National Center for Biotechnology Information.
- National Institutes of Health Office of Dietary Supplements. Choline Fact Sheet for Health Professionals.
- Parnetti L, Amenta F, Gallai V. Choline alphoscerate in cognitive decline and in acute cerebrovascular disease: an analysis of published clinical data. Mech Ageing Dev. 2001;122(16):2041-2055.
- De Jesus Moreno M. Choline alfoscerate in mild to moderate Alzheimer's dementia: a multicenter, double-blind, randomized, placebo-controlled trial. Clin Ther. 2003;25(1):178-193.
- Scapicchio P, et al. Activity of Choline Alphoscerate on Adult-Onset Cognitive Dysfunctions: A Systematic Review and Meta-Analysis. J Alzheimers Dis. 2023;92(1):59-70.
- Efficacy and safety of choline alphoscerate for amnestic mild cognitive impairment: a randomized double-blind placebo-controlled trial. BMC Geriatr. 2024;24(1):774.
- Lee G, et al. Association of L-alpha Glycerylphosphorylcholine With Subsequent Stroke Risk After 10 Years. JAMA Netw Open. 2021;4(11):e2136008.
- U.S. Food and Drug Administration. Dietary Supplements.
- Kerksick CM, et al. Acute Alpha-Glycerylphosphorylcholine Supplementation Enhances Cognitive Performance in Healthy Men. Nutrients. 2024;16(23):4240.
- EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA). Safety of L-alpha-glycerylphosphorylcholine (L-alpha-GPC) from soya phospholipids (lecithin) as a novel food pursuant to Regulation (EU) 2015/2283. EFSA Journal. 2026;24(5):e10008.